BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37233785)

  • 21. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.
    Chandekar KR; Singh H; Kumar R; Kumar S; Kakkar N; Mittal BR; Singh SK
    Clin Nucl Med; 2023 Jan; 48(1):e1-e8. PubMed ID: 36240786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparisons of [
    Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hybrid imaging with [
    Glemser PA; Rotkopf LT; Ziener CH; Beuthien-Baumann B; Weru V; Kopp-Schneider A; Schlemmer HP; Dimitrakopoulou-Strauss A; Sachpekidis C
    Cancer Imaging; 2022 Sep; 22(1):53. PubMed ID: 36138437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraindividual comparison between
    Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diverse PSMA expression in primary prostate cancer: reason for negative [
    Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective comparison of simultaneous [
    Jentjens S; Mai C; Ahmadi Bidakhvidi N; De Coster L; Mertens N; Koole M; Everaerts W; Joniau S; Oyen R; Van Laere K; Goffin K
    Eur Radiol; 2022 Feb; 32(2):901-911. PubMed ID: 34374802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective comparative study of [
    Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kit-based preparation of [
    Hong H; Wang G; Ploessl K; Zha Z; Zang J; Zhu Z; Zhu L; Kung HF
    Nucl Med Biol; 2022; 106-107():1-9. PubMed ID: 34952347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the value of
    Luo L; Zheng A; Chang R; Li Y; Gao J; Wang Z; Duan X
    Cancer Imaging; 2023 Nov; 23(1):108. PubMed ID: 37924154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [
    Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical Validation of PSMA Expression Measured by
    Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
    J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total-body PET/CT with half-dose [
    Liu Y; Li L; Qin Y; Chen Z; Zhao H; Wang X; Chen R
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):581-589. PubMed ID: 37819451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total-body [
    Wang Y; Chen Z; Zhu Y; Zhao H; Li L; Huang G; Xue W; Chen R; Liu J
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4096-4106. PubMed ID: 37578502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.